Events

Marie Skłodowska-Curie Actions Innovative Training Networks info session and workshop
JUN
Mon
24
07:00 - 16:00

This was 6 years ago

Location

University Foundation



Egmontstraat 11



1000 Brussel


Programmes
MSCA

NCP Flanders organised an info session on the 2020 call for Marie Skłodowska-Curie Actions Innovative Training Networks (ITN) and Research and Innovation Staff Exchange (RISE), in collaboration with the other Belgian National Contact Points at BELSPO and F.R.S.-FNRS.

The information session was organised to support researchers and host institutions with the preparation of their application for a Marie Skłodowska-Curie Actions Innovative Training Network and Research and Innovation Staff Exchange.

The presentations are available on the event website and below.

In the afternoon NCP Flanders and NCP FNRS co-organised a workshop on ITN proposal writing: more information

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.